We are very happy to announce that our joint project application E!114520 ACTION has been approved as a Eurostars labelled project and funding by the EUREKA Association. The project consortium is focused on development of hormone analogue drugs for treatment of autoimmune diseases. The novel drug will target the endocrine-immune interphase and the strong relationship between the level of hormones and symptom severity of autoimmune diseases such as Rheumatoid Arthritis (RA). The goal of the project is to develop a modified hormone based drugs that selectively targets immune cells without interfering with reproductive hormones. Redoxis role in the project, with a total budget of 1,6 million Euros and duration of 36 months, will be focused on evaluation of the effects of the developed drug candidates in autoimmunity using our established preclinical model platform. By combining niched and specific competences of the consortium members we aim to deliver an IND approved drug ready for first-in-human trials post-project.
A warm welcome to Jens Holmberg, PhD, the latest addition to our team. Jens has a background in preclinical inflammation research with extensive experience in inflammatory in vivo and in vitro models. During his 15 years of post-PhD-experience at Biotech & Medtech companies, Jens has also experienced chief officer positions with focus on putting the company in a scientifically competitive position and to build company value. Jens will in his position as Scientific Director support our CRO team and also function as the project leader for Redoxis work in the Neutrocure program (H2020-FETOPEN) funded by the European union. We are very happy to have Jens aboard and are looking forward to some great research during the next years.
We are continuously adding more assays and models to our portfolio while also actively improving our current models. In collaboration with Cellevate AB we have further developed our ex vivo models of inflammation. Cellevate is an innovative biotech company using nanomaterials to develop the next generation 3D cell culture systems. By using Cellevates 3D cell culture scaffolds we have gained increased stability and predictability in our immune cell stimulation assays (murine and human). These models provide a versatile tool for basic understanding and evaluation of effects on immune cell activation and can be used for tailored studies on project specific subsets, targets or biomarkers. Traditionally, in vitro models have suffered from major limitations in predictability due to altererd morphology of cells during culture. By mimicking the structures in which cells resides in vivo during evaluation of potential new therapies the likelihood of selecting biologically relevant substances for in vivo experiments can be increased.
We are now providing our assays for immune cell activation ex vivo with 3D cell culture setup. Contact us at email@example.com for more information on how we can tailor these models to suit your specific project. For more information on Cellevates 3D cell culture stystems contact firstname.lastname@example.org.
Redoxis AB has signed an agreement with Taconic Biosciences, Inc for service of characterization of cellular composition of Taconic’s humanized immune system mice. This contract covers a recurrent service spanning over three years.
“We are very excited about the collaboration with Taconic, which will beneficially impact Redoxis by adding value and financial stability to our in vitro service platform” says Malin Hultqvist Hopkins, CEO, Redoxis.
For additional information please contact:
As of beginning of March, Redoxis is now a registered trademark in the US. Redoxis has previously been a registered trademark in Sweden and European Union and was lately approved for registration by the United States Patent and Trademark Office.
“The registration of the trademark Redoxis in the US is an important step of our internationalisation strategy to increase Redoxis recognition within the American market for CRO services” says Peter Olofsson, founder and board member of Redoxis.